These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12201620)

  • 1. Switching antipsychotic medications: general recommendations and switching to amisulpride.
    Burns T; Chabannes JP; Demyttenaere K
    Curr Med Res Opin; 2002; 18(4):201-8. PubMed ID: 12201620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to amisulpride.
    Peuskens J
    Curr Med Res Opin; 2002; 18 Suppl 3():s23-8. PubMed ID: 12418609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up].
    Harangozó J; Slezák A; Borsos K; Németh O; Csukly G
    Psychiatr Hung; 2008; 23(6):464-71. PubMed ID: 19218628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
    Puech A; Fleurot O; Rein W
    Acta Psychiatr Scand; 1998 Jul; 98(1):65-72. PubMed ID: 9696517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
    Linden M; Eich FX; Pyrkosch L
    Int Clin Psychopharmacol; 2007 May; 22(3):175-8. PubMed ID: 17414744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
    Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE
    Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M; Knopf U; Henn FA; Thome J
    Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia.
    Lecrubier Y; Azorin M; Bottai T; Dalery J; Garreau G; Lempérière T; Lisoprawski A; Petitjean F; Vanelle JM
    Neuropsychobiology; 2001; 44(1):41-6. PubMed ID: 11408792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
    Burns T; Bale R
    J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
    Lin CC; Bai YM; Wang YC; Chen TT; Lai IC; Chen JY; Chen SY; Gau SS; Liou YJ
    J Clin Psychopharmacol; 2009 Dec; 29(6):529-36. PubMed ID: 19910716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.